Evidence map›Paper›PMID 36423110›Full record

ArticleViruses2022

3D-Printed EVA Devices for Antiviral Delivery and Herpes Virus Control in Genital Infection.

Victor de Carvalho Rodrigues, Iara Zanella Guterres, Beatriz Pereira Savi, Izabella Thaís Silva, Gislaine Fongaro, Gean Vitor Salmoria

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Rising role of 3D-printing in delivery of therapeutics for infectious disease.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Victor de Carvalho RodriguesNimma, Department of Mechanical Engineering, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.ORCID 0000-0001-6552-0734
Iara Zanella GuterresLaboratory of Applied Virology, Department of Microbiology, Imunology and Parasitology, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.
Beatriz Pereira SaviLaboratory of Applied Virology, Department of Microbiology, Imunology and Parasitology, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.
Izabella Thaís SilvaLaboratory of Applied Virology, Department of Microbiology, Imunology and Parasitology, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.ORCID 0000-0002-1893-4317
Gislaine FongaroLaboratory of Applied Virology, Department of Microbiology, Imunology and Parasitology, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.
Gean Vitor SalmoriaNimma, Department of Mechanical Engineering, Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil.ORCID 0000-0003-1377-6433
Universidade Federal de Santa Catarina · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herpes viruses are widespread in the human population and can cause many different diseases. Genital herpes is common and can increase the risk of HIV infection and neonatal herpes. Acyclovir is the most used drug for herpes treatment; however, it presents some disadvantages due to its poor oral bioavailability. In this study, some ethylene vinyl acetate devices with different acyclovir amounts (0, 10, and 20 wt.%) were manufactured by fused filament fabrication in two different geometries, an intrauterine device, and an intravaginal ring. Thermal analyses suggested that the crystallinity of EVA decreased up to 8% for the sample loaded with 20 wt.% of acyclovir. DSC, SEM, and FTIR analyses confirmed that the drug was successfully incorporated into the EVA matrix. Moreover, the drug release tests suggested a burst release during the first 24 h followed by a slower release rate sustained up to 80 days. Biological assays showed the biocompatibility of the EVA/ACV device, as well as a 99% reduction in vitro replication of HSV-1. Finally, the EVA presented a suitable performance for 3D printing manufacturing that can contribute to developing personalized solutions for long-term herpes treatment.

Indexed as

Antiviral AgentsHIV InfectionsAcyclovirGenitaliaHumansInfant, NewbornPrinting, Three-DimensionalSimplexvirusAcyclovirAntiviral Agents3D printingacyclovirEVAgenital herpes

Identifiers

PMID36423110
PMCPMC9696101
OpenAlexW4308973290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.